Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-036329
Filing Date
2025-03-10
Accepted
2025-03-10 16:19:50
Documents
78
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K tnya-20241231.htm   iXBRL 10-K 2926784
2 EX-4.3 tnya-ex4_3.htm EX-4.3 39729
3 EX-10.10 tnya-ex10_10.htm EX-10.10 47873
4 EX-19.1 tnya-ex19_1.htm EX-19.1 120544
5 EX-23.1 tnya-ex23_1.htm EX-23.1 3600
6 EX-31.1 tnya-ex31_1.htm EX-31.1 20619
7 EX-32.1 tnya-ex32_1.htm EX-32.1 13831
8 GRAPHIC img252959658_0.jpg GRAPHIC 546216
  Complete submission text file 0000950170-25-036329.txt   12254134

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20241231.xsd EX-101.SCH 1567952
81 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20241231_htm.xml XML 1723815
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40656 | Film No.: 25723985
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)